Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD33 CAR-T in Relapsed/Refractory AML
NCT05473221Phase 1Unknown
- Sponsor
- Zhejiang University
- Start
- Aug 2022
- Primary completion
- Aug 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD33 CAR-T in acute myeloid leukemia (AML), sponsored by Zhejiang University. Primary endpoints: Evaluation of Safety at 2 years and Changes in cytokine level after CD33 CAR-T infusion at 2 years. Status: unknown.
02
Drugs
CD33 CAR-T
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05473221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05473221.